SG11201601850YA - Therapeutics targeting truncated adenomatous polyposis coli (apc) proteins - Google Patents
Therapeutics targeting truncated adenomatous polyposis coli (apc) proteinsInfo
- Publication number
- SG11201601850YA SG11201601850YA SG11201601850YA SG11201601850YA SG11201601850YA SG 11201601850Y A SG11201601850Y A SG 11201601850YA SG 11201601850Y A SG11201601850Y A SG 11201601850YA SG 11201601850Y A SG11201601850Y A SG 11201601850YA SG 11201601850Y A SG11201601850Y A SG 11201601850YA
- Authority
- SG
- Singapore
- Prior art keywords
- apc
- proteins
- adenomatous polyposis
- polyposis coli
- therapeutics targeting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0679—Cells of the gastro-intestinal tract
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/04—Immortalised cells
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361875933P | 2013-09-10 | 2013-09-10 | |
| US201461930754P | 2014-01-23 | 2014-01-23 | |
| PCT/US2014/054987 WO2015038644A2 (en) | 2013-09-10 | 2014-09-10 | Therapeutics targeting truncated adenomatous polyposis coli (apc) proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201601850YA true SG11201601850YA (en) | 2016-04-28 |
Family
ID=52666505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201601850YA SG11201601850YA (en) | 2013-09-10 | 2014-09-10 | Therapeutics targeting truncated adenomatous polyposis coli (apc) proteins |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9856233B2 (en) |
| EP (1) | EP3044218B1 (en) |
| JP (1) | JP6506291B2 (en) |
| KR (2) | KR102300576B1 (en) |
| CN (1) | CN105873913B (en) |
| AU (2) | AU2014318821B2 (en) |
| BR (1) | BR112016005252A2 (en) |
| CA (1) | CA2924062C (en) |
| DK (1) | DK3044218T3 (en) |
| ES (1) | ES2811090T3 (en) |
| HK (1) | HK1224291A1 (en) |
| MX (1) | MX2016003082A (en) |
| RU (1) | RU2727516C2 (en) |
| SG (1) | SG11201601850YA (en) |
| WO (1) | WO2015038644A2 (en) |
| ZA (2) | ZA201601798B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014318821B2 (en) | 2013-09-10 | 2018-04-19 | Board Of Regents Of The University Of Texas System | Therapeutics targeting truncated Adenomatous Polyposis Coli (APC) proteins |
| US10082496B2 (en) | 2014-09-10 | 2018-09-25 | Board Of Regents Of The University Of Texas System | Targeting emopamil binding protein (EBP) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis |
| EP3322417B1 (en) * | 2015-07-15 | 2023-08-23 | The Board of Regents of The University of Texas System | Targeting emopamil binding protein (ebp) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis |
| EP3426654B1 (en) | 2016-03-09 | 2021-10-20 | President and Fellows of Harvard College | Direct palladium-catalyzed aromatic fluorination |
| WO2018022904A2 (en) * | 2016-07-27 | 2018-02-01 | Case Western Reserve University | Compounds and methods of promoting myelination |
| WO2019126702A1 (en) | 2017-12-22 | 2019-06-27 | Case Western Reserve University | Compounds for promoting myelination |
| CN108250111B (en) * | 2018-01-15 | 2020-04-28 | 华南理工大学 | Double-receptor organic light-emitting small molecular material and preparation method and application thereof |
| US20220024891A1 (en) * | 2018-12-04 | 2022-01-27 | The Board Of Regents Of The University Of Texas System | Therapeutics targeting mutant adenomatous polyposis coli (apc) for the treatment of cancer |
| CN113624665A (en) * | 2021-07-30 | 2021-11-09 | 中国药科大学 | Application of anti-tumor candidate compound in medicine for treating colorectal cancer and determination method |
| WO2024020156A1 (en) * | 2022-07-22 | 2024-01-25 | Biogen Ma Inc. | Emopamil-binding protein inhibitors and uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1521000A (en) | 1975-06-13 | 1978-08-09 | Syntex Puerto Rico Inc | Inhalation device |
| US4192309A (en) | 1978-09-05 | 1980-03-11 | Syntex Puerto Rico, Inc. | Inhalation device with capsule opener |
| US4227522A (en) | 1978-09-05 | 1980-10-14 | Syntex Puerto Rico, Inc. | Inhalation device |
| US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| AT396333B (en) | 1982-10-08 | 1993-08-25 | Glaxo Group Ltd | DEVICE FOR THE ADMINISTRATION OF MEDICINES TO PATIENTS, DEVICE WITH SEVERAL SUCH DEVICES AND CARRIERS WITH MEDICINE CONTAINERS HIEFUER |
| DK163640C (en) | 1985-07-30 | 1992-08-17 | Glaxo Group Ltd | DEVICE FOR ADMINISTRATING MEDICINES |
| JPH0667926B2 (en) * | 1985-11-12 | 1994-08-31 | 旭化成工業株式会社 | Cyclic isoquinoline sulfonamide derivative |
| JPH05963A (en) | 1990-04-13 | 1993-01-08 | Toray Ind Inc | Polypeptide composition |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| IL117149A0 (en) * | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
| JP2001172257A (en) | 1999-10-05 | 2001-06-26 | Fujisawa Pharmaceut Co Ltd | Organic sulfonamide compound |
| AR033517A1 (en) * | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | PIPERIDINE DERIVATIVES, PROCESS FOR THE PREPARATION AND USE OF THESE DERIVATIVES IN THE MANUFACTURE OF MEDICINES |
| CA2364178C (en) | 2000-12-05 | 2006-01-10 | Yasuhiro Katsu | N-benzenesulfonyl l-proline compounds as bradykinin antagonists |
| MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
| AU2002247208A1 (en) * | 2001-03-05 | 2002-09-19 | Icos Corporation | Selective pde3b inhibitors and use of the same in therapy |
| DE10155684A1 (en) * | 2001-11-13 | 2003-05-22 | Bayer Ag | New 1-thiazolyl-3-substituted phenyl-urea derivatives, useful for treating or preventing bacterial infection, are inhibitors of phenylalanyl-tRNA synthase |
| JPWO2004069828A1 (en) * | 2003-02-04 | 2006-05-25 | 三菱ウェルファーマ株式会社 | Piperidine compounds and their pharmaceutical uses |
| CA2567343A1 (en) * | 2004-05-20 | 2005-12-01 | Elan Pharmaceuticals, Inc. | N-cyclic sulfonamido inhibitors of gamma secretase |
| EP1866298A2 (en) * | 2005-03-31 | 2007-12-19 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
| WO2006134481A1 (en) * | 2005-06-16 | 2006-12-21 | Pfizer Inc. | Inhibitors of 11-beta hydroxysteroid dehydrogenase type 1 |
| WO2007115805A2 (en) * | 2006-04-05 | 2007-10-18 | European Molecular Biology Laboratory (Embl) | Aurora kinase inhibitors |
| AU2007234843B2 (en) * | 2006-04-07 | 2013-07-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
| US8603465B1 (en) * | 2006-08-07 | 2013-12-10 | Merck Sharp & Dohme, Corp. | Methods for treatment of polyposis |
| WO2009032703A1 (en) | 2007-08-28 | 2009-03-12 | Irm Llc | 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors |
| WO2009086303A2 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| EP2283160A4 (en) | 2008-05-07 | 2012-01-04 | Wintherix Llc | Methods for identifying compounds that modulate wnt signaling in cancer cells |
| US9623109B2 (en) * | 2008-05-27 | 2017-04-18 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of killing cells and use of same in prevention and treatment of cancer |
| TW201028421A (en) * | 2009-01-15 | 2010-08-01 | Abbott Lab | Novel benzenesulfonamides as calcium channel blockers |
| AU2012262520A1 (en) | 2011-05-27 | 2014-01-23 | Cytocure Llc | Methods, compositions, and kits for the treatment of cancer |
| CN104364391A (en) | 2012-02-08 | 2015-02-18 | 因赛特遗传学公司 | Methods and compositions relating to fusions of ROS1 for diagnosing and treating cancer |
| US20130330761A1 (en) | 2012-06-12 | 2013-12-12 | Celcuity, LLC | Whole cell assays and methods |
| AU2014318821B2 (en) | 2013-09-10 | 2018-04-19 | Board Of Regents Of The University Of Texas System | Therapeutics targeting truncated Adenomatous Polyposis Coli (APC) proteins |
-
2014
- 2014-09-10 AU AU2014318821A patent/AU2014318821B2/en not_active Ceased
- 2014-09-10 KR KR1020187002519A patent/KR102300576B1/en active IP Right Grant
- 2014-09-10 CA CA2924062A patent/CA2924062C/en active Active
- 2014-09-10 BR BR112016005252A patent/BR112016005252A2/en not_active Application Discontinuation
- 2014-09-10 KR KR1020167009391A patent/KR101824230B1/en active IP Right Grant
- 2014-09-10 US US14/482,659 patent/US9856233B2/en active Active
- 2014-09-10 ES ES14843412T patent/ES2811090T3/en active Active
- 2014-09-10 WO PCT/US2014/054987 patent/WO2015038644A2/en active Application Filing
- 2014-09-10 RU RU2016113279A patent/RU2727516C2/en not_active Application Discontinuation
- 2014-09-10 SG SG11201601850YA patent/SG11201601850YA/en unknown
- 2014-09-10 CN CN201480061472.6A patent/CN105873913B/en active Active
- 2014-09-10 JP JP2016542070A patent/JP6506291B2/en active Active
- 2014-09-10 DK DK14843412.9T patent/DK3044218T3/en active
- 2014-09-10 MX MX2016003082A patent/MX2016003082A/en unknown
- 2014-09-10 EP EP14843412.9A patent/EP3044218B1/en active Active
-
2016
- 2016-03-15 ZA ZA2016/01798A patent/ZA201601798B/en unknown
- 2016-11-02 HK HK16112580.3A patent/HK1224291A1/en unknown
-
2017
- 2017-11-27 US US15/823,150 patent/US10577344B2/en active Active
-
2018
- 2018-04-27 AU AU2018202898A patent/AU2018202898A1/en not_active Abandoned
- 2018-08-01 ZA ZA2018/05172A patent/ZA201805172B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016534140A (en) | 2016-11-04 |
| WO2015038644A3 (en) | 2015-05-14 |
| AU2014318821B2 (en) | 2018-04-19 |
| RU2016113279A (en) | 2017-10-16 |
| MX2016003082A (en) | 2016-09-13 |
| ES2811090T8 (en) | 2022-09-29 |
| ZA201805172B (en) | 2019-08-28 |
| KR101824230B1 (en) | 2018-01-31 |
| CA2924062A1 (en) | 2015-03-19 |
| US20150232444A1 (en) | 2015-08-20 |
| KR102300576B1 (en) | 2021-09-08 |
| CA2924062C (en) | 2019-05-14 |
| EP3044218B1 (en) | 2020-05-27 |
| CN105873913B (en) | 2019-12-03 |
| ZA201601798B (en) | 2022-05-25 |
| BR112016005252A2 (en) | 2017-09-12 |
| WO2015038644A2 (en) | 2015-03-19 |
| CN105873913A (en) | 2016-08-17 |
| HK1224291A1 (en) | 2017-08-18 |
| KR20180011890A (en) | 2018-02-02 |
| EP3044218A2 (en) | 2016-07-20 |
| KR20160049014A (en) | 2016-05-04 |
| US9856233B2 (en) | 2018-01-02 |
| DK3044218T3 (en) | 2020-07-27 |
| AU2018202898A1 (en) | 2018-05-17 |
| US20190135776A1 (en) | 2019-05-09 |
| RU2727516C2 (en) | 2020-07-22 |
| US10577344B2 (en) | 2020-03-03 |
| ES2811090T3 (en) | 2021-03-10 |
| EP3044218A4 (en) | 2017-02-22 |
| AU2014318821A1 (en) | 2016-04-14 |
| JP6506291B2 (en) | 2019-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201805172B (en) | Therapeutics targeting truncated adenomatous polyposis coli (apc) proteins | |
| IL245544A0 (en) | Drug delivery system | |
| EP2948202A4 (en) | Impeller position compensation using field oriented control | |
| IL233621A (en) | Fungicidal pyrazole mixtures | |
| EP2961302A4 (en) | Blending system | |
| EP3038638A4 (en) | Small cationic anti-biofilm and idr peptides | |
| EP3345282A4 (en) | Usb power delivery dead-battery control | |
| HK1222852A1 (en) | Diaminoheteroaryl substituted pyrazoles | |
| DK2994154T3 (en) | ANTIMICROBIAL PEPTID | |
| ZA201508015B (en) | Solid forms of fungicidal pyrazoles | |
| GB201308917D0 (en) | Delivery | |
| HK1208344A1 (en) | Cell-specific targeting using nanostructured delivery systems | |
| EP2961447A4 (en) | Direct pressure-mediated intra-bone delivery system for cellular therapeutics | |
| DK3288955T3 (en) | Bortezomib-based delivery system | |
| DE112014004954T8 (en) | delivery system | |
| DE112014004938T8 (en) | delivery system | |
| HK1220366A1 (en) | Protein formulations | |
| ZA201506586B (en) | Herbicidal composition | |
| GB201306981D0 (en) | Delivery system | |
| GB201304973D0 (en) | Recombinant protein | |
| EP3088000A4 (en) | Vaccine targeting il-17a | |
| GB201316666D0 (en) | Targeting molecule | |
| PL2943067T3 (en) | Fungicidal composition | |
| GB201308860D0 (en) | Delivery peptides | |
| GB201510182D0 (en) | Improvements in antimicrobial drugs |